Weiss Ratings Reiterates "Hold (C-)" Rating for Zimmer Biomet (NYSE:ZBH)

Key Points

• Weiss Ratings has reiterated a "Hold (C-)" rating for Zimmer Biomet (NYSE:ZBH), highlighting a cautious outlook on the stock.
• Other analysts have shown more optimism, with several raising Zimmer Biomet's target price and assigning multiple "Buy" ratings, contributing to a consensus price target of $111.94.
• Zimmer Biomet's stock recently traded at $102.50, reflecting a slight decline, while the company reported a 7% year-over-year revenue growth along with better-than-expected earnings.

Zimmer Biomet (NYSE:ZBH - Get Free Report)'s stock had its "hold (c-)" rating reissued by equities researchers at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

Other research analysts have also issued research reports about the company. BTIG Research lifted their target price on Zimmer Biomet from $118.00 to $122.00 and gave the company a "buy" rating in a report on Monday, October 13th. Rothschild Redb raised Zimmer Biomet to a "strong-buy" rating in a report on Thursday, September 18th. Stifel Nicolaus lifted their target price on Zimmer Biomet from $115.00 to $118.00 and gave the company a "buy" rating in a report on Friday, September 19th. Royal Bank Of Canada set a $111.00 price target on Zimmer Biomet in a research report on Friday, October 10th. Finally, Canaccord Genuity Group reiterated a "hold" rating and set a $101.00 price target on shares of Zimmer Biomet in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $111.94.

Zimmer Biomet Stock Performance

Shares of ZBH stock traded down $0.66 on Friday, hitting $102.50. 392,207 shares of the stock were exchanged, compared to its average volume of 1,889,507. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $20.30 billion, a PE ratio of 25.00, a P/E/G ratio of 2.39 and a beta of 0.67. Zimmer Biomet has a one year low of $89.22 and a one year high of $114.72. The firm's 50 day moving average is $101.86 and its two-hundred day moving average is $97.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. The business had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the firm's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company's stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.39% of the company's stock.

Hedge Funds Weigh In On Zimmer Biomet

Large investors have recently modified their holdings of the company. Truist Financial Corp raised its holdings in shares of Zimmer Biomet by 34.4% during the 2nd quarter. Truist Financial Corp now owns 26,819 shares of the medical equipment provider's stock valued at $2,446,000 after buying an additional 6,867 shares in the last quarter. OneDigital Investment Advisors LLC purchased a new position in shares of Zimmer Biomet during the 1st quarter valued at about $269,000. State of Alaska Department of Revenue raised its holdings in shares of Zimmer Biomet by 89.8% during the 2nd quarter. State of Alaska Department of Revenue now owns 44,261 shares of the medical equipment provider's stock valued at $4,036,000 after buying an additional 20,945 shares in the last quarter. Thomasville National Bank raised its holdings in shares of Zimmer Biomet by 3.0% during the 2nd quarter. Thomasville National Bank now owns 105,805 shares of the medical equipment provider's stock valued at $9,650,000 after buying an additional 3,053 shares in the last quarter. Finally, Bridge Creek Capital Management LLC raised its holdings in shares of Zimmer Biomet by 12.3% during the 2nd quarter. Bridge Creek Capital Management LLC now owns 30,133 shares of the medical equipment provider's stock valued at $2,748,000 after buying an additional 3,297 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.